Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cumali Efe

Showing results (121-130 of 136) with videos related to

Pageof 14
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 13, 2019
Rapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 MonthsSimon Pape, Tom J G Gevers, Jan Maarten Vrolijk, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 16, 2020
High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiationSimon Pape, Tom J G Gevers, Jan Maarten Vrolijk, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 13, 2017
Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune HepatitisCumali Efe, Hannes Hagström, Henriette Ytting, et al.
Journal of Gastroenterology and Hepatology|August 14, 2020
Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcomeCumali Efe, Murat Torgutalp, Ida Henriksson, et al.
Hepatology (Baltimore, Md.)|September 9, 2024
Efficacy and safety of infliximab in patients with autoimmune hepatitisCumali Efe, Ellina Lytvyak, Tuğçe Eşkazan, et al.
Hepatology International|February 4, 2022
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitisHong You, Xiong Ma, Cumali Efe, et al.
The American Journal of Gastroenterology|June 27, 2019
Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary CholangitisCumali Efe, Koray Taşçilar, Ida Henriksson, et al.
JHEP Reports : Innovation in Hepatology|November 28, 2022
Histological and serological features of acute liver injury after SARS-CoV-2 vaccinationGreta Codoni, Theresa Kirchner, Bastian Engel, et al.
Journal of Autoimmunity|September 11, 2022
SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitisCumali Efe, Koray Taşçılar, Alessio Gerussi, et al.
European Journal of Gastroenterology & Hepatology|January 28, 2026
Clinical course and prognostic risk factors of SARS-CoV-2 vaccine-related hepatitis: differentiating severe acute respiratory syndrome coronavirus 2 vaccine-associated liver injury from autoimmune hepatitisDonald Malino, Greta Codoni, Theresa Kirchner, et al.
Pageof 14

Showing results (121-130 of 136) with videos related to

Sort By:
Pageof 14
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 13, 2019
Rapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 MonthsSimon Pape, Tom J G Gevers, Jan Maarten Vrolijk, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 16, 2020
High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiationSimon Pape, Tom J G Gevers, Jan Maarten Vrolijk, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 13, 2017
Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune HepatitisCumali Efe, Hannes Hagström, Henriette Ytting, et al.
Journal of Gastroenterology and Hepatology|August 14, 2020
Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcomeCumali Efe, Murat Torgutalp, Ida Henriksson, et al.
Hepatology (Baltimore, Md.)|September 9, 2024
Efficacy and safety of infliximab in patients with autoimmune hepatitisCumali Efe, Ellina Lytvyak, Tuğçe Eşkazan, et al.
Hepatology International|February 4, 2022
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitisHong You, Xiong Ma, Cumali Efe, et al.
The American Journal of Gastroenterology|June 27, 2019
Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary CholangitisCumali Efe, Koray Taşçilar, Ida Henriksson, et al.
JHEP Reports : Innovation in Hepatology|November 28, 2022
Histological and serological features of acute liver injury after SARS-CoV-2 vaccinationGreta Codoni, Theresa Kirchner, Bastian Engel, et al.
Journal of Autoimmunity|September 11, 2022
SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitisCumali Efe, Koray Taşçılar, Alessio Gerussi, et al.
European Journal of Gastroenterology & Hepatology|January 28, 2026
Clinical course and prognostic risk factors of SARS-CoV-2 vaccine-related hepatitis: differentiating severe acute respiratory syndrome coronavirus 2 vaccine-associated liver injury from autoimmune hepatitisDonald Malino, Greta Codoni, Theresa Kirchner, et al.
Pageof 14